Income statement, balance sheet and cash flow statement for the last 1 fiscal years, taken from the XBRL data Bodhi Tree Biotechnology Inc files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
Revenue
0.02
General and administrative
0.16
Operating income
-0.15
Other non-operating income
0
Pre-tax income
-0.15
Income tax
0
Net income
-0.15
EPS, basic
-0.01
EPS, diluted
-0.01
Shares, basic (weighted)
25.4
Shares, diluted (weighted)
25.4
Balance sheet
FY2025
Cash and equivalents
0.11
Other current assets
0.01
Total assets
0.12
Total liabilities
0
Paid-in capital
0.33
Retained earnings
-0.21
Shareholders' equity
0.12
Total equity
0.12
Total liabilities and equity
0.12
Shares outstanding
25.4
Cash flow statement
FY2025
Net income
-0.15
Cash from operations
-0.15
Net change in cash
-0.15
Income taxes paid
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.28 on October 22, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-310.2%
Operating income / revenue.
Pre-tax margin
-310.2%
Pre-tax income / revenue.
Net margin
-313.6%
Net income / revenue.
Operating cash flow margin
-312.2%
Cash from operations / revenue.
Return on equity (ROE)
-839.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-633.2%
Net income / average total assets.
Return on invested capital (ROIC)
-921.7%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Balance sheet health
Metric
Value
How it is calculated
Quick ratio
0.89x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.89x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.00
Cash from operations / diluted weighted shares.
Book value per share
$0.00
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
194x
Market cap / revenue.
P/B
519x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
519x
Market cap / tangible book value, when positive.
EV/Sales
194x
Enterprise value / revenue.
Earnings yield
-1.6%
Net income / market cap (the inverse of P/E).
What was Bodhi Tree Biotechnology Inc's revenue in fiscal 2025?
Bodhi Tree Biotechnology Inc reported revenue of $17.0K for fiscal 2025.
Was Bodhi Tree Biotechnology Inc profitable in fiscal 2025?
No. It reported a net loss of $149.7K.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.